Literature DB >> 31461381

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.

Erica C Nakajima1, Evan J Lipson1, Julie R Brahmer1.   

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

Entities:  

Year:  2019        PMID: 31461381     DOI: 10.1200/JCO.19.01623

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy.

Authors:  Bongseo Choi; Dong-Hyun Kim
Journal:  Adv Nanobiomed Res       Date:  2021-08-02

2.  Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.

Authors:  Xin Zhao; Fengwei Gao; Jie Yang; Hua Fan; Qingyun Xie; Kangyi Jiang; Jie Gong; Benjian Gao; Qian Yang; Zehua Lei
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 3.  Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers.

Authors:  Haoran Li; Kamal K Sahu; Benjamin L Maughan
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

4.  Pembrolizumab on pre-existing inclusion body myositis: a case report.

Authors:  Naohiro Uchio; Atsushi Unuma; Toshiyuki Kakumoto; Masao Osaki; Yoshitaka Zenke; Kenichi Sakuta; Akatsuki Kubota; Yoshikazu Uesaka; Tatsushi Toda; Jun Shimizu
Journal:  BMC Rheumatol       Date:  2020-09-16

5.  Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.

Authors:  Lina María Serna-Higuita; Teresa Amaral; Andrea Forschner; Ulrike Leiter; Lukas Flatz; Olivia Seeber; Ioannis Thomas; Claus Garbe; Thomas Kurt Eigentler; Peter Martus
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 6.  Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.

Authors:  Bénédicte Delire; Eleonora De Martin; Lucy Meunier; Dominique Larrey; Yves Horsmans
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

7.  Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report.

Authors:  Tian-Tian Xuan; Guang-Yi Li; Si-Bo Meng; Zhan-Mei Wang; Lin-Li Qu
Journal:  World J Clin Cases       Date:  2022-08-16       Impact factor: 1.534

8.  Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.

Authors:  Charles Dolladille; Stéphane Ederhy; Marion Sassier; Jennifer Cautela; Franck Thuny; Ariel A Cohen; Sophie Fedrizzi; Basile Chrétien; Angélique Da-Silva; Anne-Flore Plane; Damien Legallois; Paul U Milliez; Véronique Lelong-Boulouard; Joachim Alexandre
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.